Literature DB >> 18721769

Unrelated cord blood transplantation for severe aplastic anemia.

Ayami Yoshimi1, Seiji Kojima2, Shuichi Taniguchi3, Junichi Hara4, Toshimitsu Matsui5, Yoshiyuki Takahashi6, Hiroshi Azuma7, Koji Kato8, Tokiko Nagamura-Inoue9, Shunro Kai10, Shunichi Kato11.   

Abstract

In the present study we evaluated the feasibility of unrelated cord blood transplantation (UCBT) in patients with severe aplastic anemia (SAA). The outcome of 31 SAA patients (median age 28; range: 0.9-72.3 years old) who received UCBT was analyzed. The cumulative incidences of the neutrophil and platelet recovery after UCBT were 54.8 and 72.2%, respectively (95% confidence interval [CI] = 36.0%-70.3% and 51.3%-85.3%, respectively). The cumulative incidences of grade > or =II acute and chronic graft-versus-host disease (aGVHD, cGVHD) were 17.1% (95% CI = 6.2%-32.8%) and 19.7% (95% CI = 6.2%-38.8%), respectively. Currently, 13 patients are alive, having survived for 33.7 months (median; range: 6-77 months) after UCBT. The probability of overall survival (OS) at 2 years was 41.1% (95% CI = 23.8%-57.7%). A conditioning regimen that included low-dose total body irradiation (TBI) (2-5 Gy), fludarabine, and cyclophosphamide resulted in a favorable OS (80%; 95% CI = 20.4%-96.9%). This result suggests that UCBT using the optimal conditioning regimen can be a salvage treatment for patients without a suitable bone marrow donor and warrants evaluation in further prospective studies.

Entities:  

Mesh:

Year:  2008        PMID: 18721769     DOI: 10.1016/j.bbmt.2008.07.003

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  26 in total

Review 1.  How I treat acquired aplastic anemia.

Authors:  Phillip Scheinberg; Neal S Young
Journal:  Blood       Date:  2012-04-19       Impact factor: 22.113

2.  Allogeneic hematopoietic cell transplantation for severe aplastic anemia: similar long-term overall survival after transplantation with related donors compared to unrelated donors.

Authors:  B K Mortensen; N Jacobsen; C Heilmann; H Sengeløv
Journal:  Bone Marrow Transplant       Date:  2015-10-05       Impact factor: 5.483

3.  Optimization of therapy for severe aplastic anemia based on clinical, biologic, and treatment response parameters: conclusions of an international working group on severe aplastic anemia convened by the Blood and Marrow Transplant Clinical Trials Network, March 2010.

Authors:  Michael A Pulsipher; Neal S Young; Jakub Tolar; Antonio M Risitano; H Joachim Deeg; Paolo Anderlini; Rodrigo Calado; Seiji Kojima; Mary Eapen; Richard Harris; Phillip Scheinberg; Sharon Savage; Jaroslaw P Maciejewski; Ramon V Tiu; Nancy DiFronzo; Mary M Horowitz; Joseph H Antin
Journal:  Biol Blood Marrow Transplant       Date:  2010-10-27       Impact factor: 5.742

Review 4.  Alternative donor transplant of benign primary hematologic disorders.

Authors:  J Tolar; P Sodani; H Symons
Journal:  Bone Marrow Transplant       Date:  2015-02-09       Impact factor: 5.483

5.  Haploidentical hematopoietic SCT for acquired severe aplastic anemia using post-transplant high-dose CY.

Authors:  N Gupta; D Choudhary; S K Sharma; V Khandelwal; M Dhamija
Journal:  Bone Marrow Transplant       Date:  2014-10-06       Impact factor: 5.483

6.  Refinement of treatment strategies in ex vivo T-cell-depleted haploidentical SCT for pediatric patients.

Authors:  H J Im; K N Koh; J K Suh; S W Lee; E S Choi; S Jang; S W Kwon; C-J Park; J J Seo
Journal:  Bone Marrow Transplant       Date:  2014-10-13       Impact factor: 5.483

Review 7.  Cord blood transplantation for bone marrow failure syndromes: state of art.

Authors:  Simona Pagliuca; Annalisa Ruggeri; Régis Peffault de Latour
Journal:  Stem Cell Investig       Date:  2019-12-05

8.  Immunosuppressive therapy versus alternative donor hematopoietic stem cell transplantation for children with severe aplastic anemia who lack an HLA-matched familial donor.

Authors:  Y B Choi; E S Yi; J W Lee; K W Sung; H H Koo; K H Yoo
Journal:  Bone Marrow Transplant       Date:  2016-09-26       Impact factor: 5.483

Review 9.  Advancement of pediatric blood and marrow transplantation research in North America: priorities of the Pediatric Blood and Marrow Transplant Consortium.

Authors:  Michael A Pulsipher; Edwin M Horwitz; Ann E Haight; Richard Kadota; Allen R Chen; Haydar Frangoul; Laurence J N Cooper; David A Jacobsohn; Rakesh K Goyal; David Mitchell; Michael L Nieder; Gregory Yanik; Morton J Cowan; Sandeep Soni; Sharon Gardner; Shalini Shenoy; Douglas Taylor; Mitchell Cairo; Kirk R Schultz
Journal:  Biol Blood Marrow Transplant       Date:  2010-01-14       Impact factor: 5.742

Review 10.  Aplastic anemia: pathophysiology and treatment.

Authors:  Neal S Young; Andrea Bacigalupo; Judith C W Marsh
Journal:  Biol Blood Marrow Transplant       Date:  2009-09-24       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.